Related Experiment Video
Updated: Aug 9, 2026

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
Published on: May 10, 2022
Iron in liver diseases other than hemochromatosis
H L Bonkovsky1, B F Banner, R W Lambrecht
1Department of Medicine, University of Massachusetts Medical Center, Worcester 01655, USA.
Abstract:
There is growing evidence that normal or only mildly increased amounts of iron in the liver can be damaging, particularly when they are combined with other hepatotoxic factors such as alcohol, porphyrogenic drugs, or chronic viral hepatitis. Iron enhances the pathogenicity of microorganisms, adversely affects the function of macrophages and lymphocytes, and enhances fibrogenic pathways, all of which may increase hepatic injury due to iron itself or to iron and other factors. Iron may also be a co-carcinogen or promoter of hepatocellular carcinoma, even in patients without HC or cirrhosis. Based on this and other evidence, we hope that the era of indiscriminate iron supplementation will come to an end. Bloodletting, a therapy much in vogue 2 centuries ago, is deservedly enjoying a renaissance, based on our current understanding of the toxic effects of iron and the benefits of its depletion.
Insights
Excessive iron in the liver, even at normal levels, can cause damage, especially with other toxins. This research suggests ending indiscriminate iron supplementation and revisiting bloodletting for iron depletion.
Area of Science:
- Hepatology
- Toxicology
- Immunology
Background:
- Growing evidence suggests that even normal or mildly elevated liver iron can be harmful.
- Iron toxicity is exacerbated by co-factors like alcohol, certain drugs, and viral hepatitis.
Purpose of the Study:
- To review the detrimental effects of iron accumulation in the liver.
- To advocate for a reevaluation of iron supplementation practices and explore therapeutic phlebotomy.
Main Methods:
- Literature review of studies on iron metabolism and liver disease.
- Analysis of iron's role in hepatic injury and carcinogenesis.
- Examination of historical and current therapeutic approaches for iron overload.
Main Results:
- Iron enhances microbial pathogenicity and impairs immune cell function (macrophages, lymphocytes).
- Iron promotes fibrogenic pathways, increasing hepatic injury.
- Iron acts as a co-carcinogen or promoter for hepatocellular carcinoma, even without pre-existing liver conditions.
Conclusions:
- Indiscriminate iron supplementation should cease due to potential harm.
- Therapeutic phlebotomy (bloodletting) is a viable and beneficial treatment for iron depletion.
- Understanding iron's toxicity supports a shift in clinical practice towards cautious iron management.
Related Concept Videos
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Microbes and Other Elemental Cycles
Cirrhosis I: Introduction
Portal Hypertension
Jaundice

